Diplomat Pharmacy, Inc. (DPLO) EPS Estimated At $0.23 as of May, 14

April 17, 2018 - By Andrea Pope

Diplomat Pharmacy, Inc. (NYSE:DPLO) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.89. That’s change of 0.45, from 2017Q3’s 1.44. 17 investors sold all, 40 reduced holdings as Diplomat Pharmacy, Inc. ratio increased. 63 grew stakes while 45 funds bought stakes. Funds hold 47.12 million shares thus 4.65% less from 2017Q3’s 49.42 million shares.
Point72 Asset Mgmt Ltd Partnership owns 61,640 shs. Com National Bank reported 0.01% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Usa Financial Portformulas Corp stated it has 27,105 shs. Citigroup Inc has invested 0% of its capital in Diplomat Pharmacy, Inc. (NYSE:DPLO). Chicago Equity Prtn Ltd Liability Company holds 60,515 shs or 0.04% of its capital. Ameritas Investment Ptnrs Inc owns 0% invested in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 3,949 shs. Pacad Investment has invested 0.01% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Voya Mngmt Ltd Co owns 21,641 shs. Alabama-based Weiss Multi has invested 0.01% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Northwestern Mutual Wealth Mgmt Company holds 165 shs. The New York-based Fred Alger Management has invested 0.06% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Huntington National Bank & Trust accumulated 1,405 shs. Iguana Healthcare Mngmt Limited Liability Com invested in 0.65% or 50,000 shs. Principal Gru invested in 0.01% or 360,765 shs. Alphamark Advsrs Ltd Liability Company stated it has 0.32% in Diplomat Pharmacy, Inc. (NYSE:DPLO).

Diplomat Pharmacy, Inc. had 1 insider sale and 0 buys since March 9, 2018. This’s net activity of $44.40 million.

On May, 14 Diplomat Pharmacy, Inc. (NYSE:DPLO)’s earnings report is expected by WallStreet, as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $0.23. That’s up 21.05 % from last year’s $0.19 earnings per share. If DPLO’s EPS is $0.23 the profit will hit $17.04 million for 22.95 P/E. Wall Street forecasts 27.78 % EPS growth as of May, 14. DPLO reached $21.11 on during the last trading session after $0.86 change.Currently Diplomat Pharmacy, Inc. is uptrending after 34.38% change in last April 17, 2017. DPLO has 341,944 shares volume. DPLO outperformed by 22.83% the S&P 500.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Ratings Coverage

In total 10 analysts cover Diplomat Pharmacy (NYSE:DPLO). “Buy” rating has 5, “Sell” are 0, while 5 are “Hold”. 50% are bullish. 20 are the (NYSE:DPLO)’s analyst reports since October 24, 2017 according to StockzIntelligence Inc. On Tuesday, February 27 Robert W. Baird maintained Diplomat Pharmacy, Inc. (NYSE:DPLO) rating. Robert W. Baird has “Hold” rating and $22.0 target. On Friday, October 27 the stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) earned “Buy” rating by Robert W. Baird. On Tuesday, February 27 the rating was maintained by Wells Fargo with “Market Perform”. The company rating was downgraded by Deutsche Bank on Friday, February 2. The company rating was maintained by Mizuho on Tuesday, November 7. On Friday, March 2 the company was upgraded by Deutsche Bank. The stock rating was maintained by Mizuho with “Hold” on Tuesday, October 24. The company rating was upgraded by Credit Suisse on Thursday, January 25. On Tuesday, February 27 the stock has “Outperform” rating by Leerink Swann. On Tuesday, November 7 the stock of Diplomat Pharmacy, Inc. (NYSE:DPLO) has “Market Perform” rating given by Leerink Swann.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States.The company has $1.56 billion market cap. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers.92.61 is the P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.